Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TERN Terns Pharmaceuticals, Inc.

Closed 01-13 16:00:00 EST

34.45

+0.34

+1.00%

盘后34.50

+0.05+0.15%

19:57 EST

High35.60	Low33.72	Vol2.21M
Open34.08	D1 Closing34.11	Amplitude5.51%
Mkt Cap3.76B	Tradable Cap2.77B	Total Shares109.00M
T/O77.03M	T/O Rate2.76%	Tradable Shares80.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TERN","market":"US","secType":"STK","nameCN":"Terns Pharmaceuticals, Inc.","latestPrice":34.45,"timestamp":1768338000000,"preClose":34.11,"halted":0,"volume":2213511,"hourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.45,"latestTime":"19:57 EST","volume":7970,"amount":275055.4425,"timestamp":1768352244846},"delay":0,"floatShares":80316400,"shares":109000000,"eps":-1.031852,"marketStatus":"Closed","change":0.34,"latestTime":"01-13 16:00:00 EST","open":34.08,"high":35.6,"low":33.72,"amount":77030231.497242,"amplitude":0.055116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.031852,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":5,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":34.11,"preHourTrading":{"tag":"盘前","latestPrice":33.91,"preClose":34.11,"latestTime":"09:20 EST","volume":618,"amount":21031.387896,"timestamp":1768314037312},"postHourTrading":{"tag":"盘后","latestPrice":34.5,"preClose":34.45,"latestTime":"19:57 EST","volume":7970,"amount":275055.4425,"timestamp":1768352244846},"volumeRatio":0.825825,"impliedVol":0.6778,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/TERN/tweets","defaultTab":"tweets","newsList":[{"id":"2603682166","title":"De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682166?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:36","pubTimestamp":1768311398,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Evan Seigerman has maintained their bullish stance on TERN stock, giving a Buy rating today. Evan Seigerman has given his Buy r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/de-risked-cml-lead-asset-robust-trial-strategy-and-1b-cash-runway-underscore-buy-rating-on-terns-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/de-risked-cml-lead-asset-robust-trial-strategy-and-1b-cash-runway-underscore-buy-rating-on-terns-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN"],"gpt_icon":0},{"id":"2603507504","title":"TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2603507504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603507504?lang=en_us&edition=fundamental","pubTime":"2026-01-13 17:55","pubTimestamp":1768298129,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has reiterated their bullish stance on TERN stock, giving a Buy rating on January 8. Andy Hsieh has given his Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tern-701s-superior-efficacy-and-safety-in-cml-underpin-buy-rating-and-top-2026-pick-on-terns-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tern-701s-superior-efficacy-and-safety-in-cml-underpin-buy-rating-and-top-2026-pick-on-terns-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPN","TERN"],"gpt_icon":0},{"id":"2602551045","title":"Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551045","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602551045?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:13","pubTimestamp":1768223606,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals Inc.  highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia , in its latest corporate presentation. TERN-701 demonstrated a major molecular response  rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4Tc7PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2601330470","title":"Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2601330470","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601330470?lang=en_us&edition=fundamental","pubTime":"2026-01-08 10:46","pubTimestamp":1767840395,"startTime":"0","endTime":"0","summary":"In recent weeks, Terns Pharmaceuticals reported encouraging Phase 1 data and strong enrollment for its CARDINAL trial of TERN-701 in chronic myeloid leukemia, alongside receiving US FDA Fast Track designation for the therapy in late 2025.\nThe company also completed an upsized public offering of more than 18,600,000 shares at US$40.00 each, raising about US$747,500,000 in gross proceeds and extending its reported cash runway into 2031.\nNext, we’ll examine how TERN-701’s Fast Track status and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/will-fast-track-tern-701-status-and-7475-million-raise-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/will-fast-track-tern-701-status-and-7475-million-raise-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TERN.AU","TERN","BK7083"],"gpt_icon":0},{"id":"2601892503","title":"Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892503","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601892503?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:05","pubTimestamp":1767819900,"startTime":"0","endTime":"0","summary":"CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214915/0/en/Terns-Pharmaceuticals-to-Highlight-2026-Priorities-and-Program-Milestones-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TERN","IE00BKVL7J92.USD","LU0320765646.SGD","LU0267386448.USD","BK4588","BK4534","LU1732800096.USD","LU2357305700.SGD","LU1244550221.USD","LU0029874061.USD","LU1363072403.SGD","LU2089283258.USD","LU0006306889.USD","LU0557290698.USD","XLV","LU2111349929.HKD","LU1791710582.SGD","LU2028103732.USD","BK4137","BK4127","LU0158827781.USD","LU1989772840.SGD","LU2023251221.USD","LU1720051108.HKD","LU0225283273.USD","LU1074936037.SGD","LABU","LU1732799900.SGD","LU0528227936.USD","LU0795875169.SGD","LU1989772923.USD","LU0234570918.USD","XBI","LU0106831901.USD","LU1244550577.SGD","LU0971096721.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU1791710400.SGD","BK4581","LU0098860793.USD","HCSG","BK4585","LU0106261372.USD","LU0912757837.SGD","LU1720051017.SGD","LU0128526141.USD","LU0158827948.USD","LU2271345857.HKD"],"gpt_icon":0},{"id":"2601420968","title":"Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601420968","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601420968?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:26","pubTimestamp":1767749191,"startTime":"0","endTime":"0","summary":"Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLRbLtj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2600789098","title":"Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2600789098","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600789098?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:05","pubTimestamp":1767387908,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals Inc. has granted equity inducement awards to two new employees under its 2022 Employment Inducement Award Plan. The awards include options to purchase a total of 312,000 shares of Terns common stock, with an exercise price of $40.40 per share, reflecting the closing price on December 31, 2025. The options have a 10-year term and will vest over four years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL97djS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","TERN","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","BK4112","SG9999014005.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2600098709","title":"Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098709","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098709?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:05","pubTimestamp":1767387900,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Jan.  02, 2026  (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/02/3212281/0/en/Terns-Pharmaceuticals-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-C-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","LU0098860793.USD","BK4585","LU1244550577.SGD","BK4559","LU1267930227.SGD","BK4007","LU0106831901.USD","BK4504","LU1668664300.SGD","LU2125154778.USD","LU0310800965.SGD","LU2236285917.USD","LU1366192091.USD","IE00BSNM7G36.USD","LU1244550494.USD","LU1244550221.USD","LU0162691827.USD","LU0980610538.SGD","LU2462157665.USD","LU2125154935.USD","LU2360032135.SGD","LU0170899867.USD","BK4566","LU0648001328.SGD","LU0072461881.USD","LU0128525689.USD","LU2417539215.USD","LU0130102774.USD","BK4207","TERN","BK4588","BK4534","LU0130517989.USD","LU1162221912.USD","LU0052756011.USD","LU0477156953.USD","LU0320765646.SGD","LU1791807156.HKD","LU2456880835.USD"],"gpt_icon":0},{"id":"2591600517","title":"Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701","url":"https://stock-news.laohu8.com/highlight/detail?id=2591600517","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591600517?lang=en_us&edition=fundamental","pubTime":"2025-12-16 16:21","pubTimestamp":1765873275,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals (TERN) just paired upbeat CARDINAL trial data for its CML candidate TERN-701 with aggressive financing moves, including a $650 million follow on equity raise, reshaping both its balance sheet and growth runway.\nSee our latest analysis for Terns Pharmaceuticals.\nThe CARDINAL data and follow on raises land on top of a huge run, with a roughly 95 percent 1 month share price return and a 547 percent 1 year total shareholder return signaling powerful, still building momentum...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/terns-pharmaceuticals-tern-valuation-check-after-strong-card","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/terns-pharmaceuticals-tern-valuation-check-after-strong-card","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2590541590","title":"Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541590?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487100,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Dec.  11, 2025  (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its pr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204296/0/en/Terns-Announces-Closing-of-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN","BK4007","USA"],"gpt_icon":0},{"id":"2590194125","title":"Terns Pharmaceuticals Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2590194125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590194125?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:49","pubTimestamp":1765460940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TERN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 08:49 ET (13:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN"],"gpt_icon":0},{"id":"2590394985","title":"Terns Pharmaceuticals Stock Rises on Public Offerings to Fund TERN-701","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394985","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394985?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:31","pubTimestamp":1765384260,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals' stock continued its upward momentum after the company announced public offerings to fund further development of its cancer treatment, which recently performed well in a trial.The stock climbed 8% to $46.10 on Wednesday, at one point touching an all-time high of $48.26. Shares have increased more than eightfold this year, and most of that gain has occurred in November and December.The Foster City, Calif., oncology company said Wednesday morning it had begun a proposed underwritten public offering of $400 million worth of its shares and pre-funded warrants.Terns also expects to grant underwriters a 30-day option to buy up to an additional $60 million of shares.Later on Wednesday, Terns said it would price a separate public offering of 16.3 million shares at $40 a share. The gross proceeds of that offering are expected to be $650 million, it said.The proceeds of both offerings will go toward funding research, clinical trials, development and manufacturing for TERN-7","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2590351345","title":"Terns Pharmaceuticals Inc : Jefferies Raises Target Price to $70 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2590351345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590351345?lang=en_us&edition=fundamental","pubTime":"2025-12-10 23:07","pubTimestamp":1765379274,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG10W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2590370813","title":"Terns Pharmaceuticals Inc - Prices Upsized Offering of 16,250,000 Shares at $40.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2590370813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590370813?lang=en_us&edition=fundamental","pubTime":"2025-12-10 12:30","pubTimestamp":1765341000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA8BPQKH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2590346276","title":"Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346276","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346276?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:59","pubTimestamp":1765285143,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals (TERN) has an average rating of buy and mean price target of $44.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","TERN"],"gpt_icon":0},{"id":"2590717346","title":"Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster","url":"https://stock-news.laohu8.com/highlight/detail?id=2590717346","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590717346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:51","pubTimestamp":1765284660,"startTime":"0","endTime":"0","summary":"Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/cancer_0.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/cancer_0.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49277005/tiny-biotech-terns-takes-aim-at-novartis-leukemia-blockbuster","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49277005/tiny-biotech-terns-takes-aim-at-novartis-leukemia-blockbuster","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0211331839.USD","IE0009355771.USD","BK4007","IE00B4R5TH58.HKD","IE00B2B36J28.USD","TERN","LU0320765489.SGD","BK4532","LU0208291251.USD","NVS","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","ELVN","BK4588","IE00BJT1NW94.SGD","BK4585","BK4578","LU0070302665.USD"],"gpt_icon":0},{"id":"2590438643","title":"Terns Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590438643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590438643?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:43","pubTimestamp":1765280580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TERN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 06:43 ET (11:43 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN"],"gpt_icon":0},{"id":"2590348394","title":"BRIEF-Terns Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348394","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348394?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:23","pubTimestamp":1765279417,"startTime":"0","endTime":"0","summary":"BRIEF-Terns Announces Proposed Public OfferingDec 9 (Reuters) - Terns Pharmaceuticals Inc TERN.O:TERNS ANNOUNCES PROPOSED PUBLIC OFFERINGTERNS PHARMACEUTICALS INC - ANNOUNCES $400 MILLION PUBLIC OFFER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA9RQVNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2590787310","title":"Terns Pharmaceuticals Inc - to Use Proceeds for Research and Tern-701 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590787310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590787310?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:12","pubTimestamp":1765278775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA9RQVNV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2590310738","title":"Terns Pharmaceuticals Inc - Grants Option for Additional $60 Mln Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590310738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590310738?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:12","pubTimestamp":1765278775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA9RQVNV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TERN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ternspharma.com","stockEarnings":[{"period":"1week","weight":-0.1296},{"period":"1month","weight":-0.242},{"period":"3month","weight":3.2215},{"period":"6month","weight":5.4725},{"period":"1year","weight":5.8084},{"period":"ytd","weight":-0.1557}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.154936},{"month":2,"riseRate":0.5,"avgChangeRate":-0.028286},{"month":3,"riseRate":0.2,"avgChangeRate":-0.064234},{"month":4,"riseRate":0.4,"avgChangeRate":-0.078723},{"month":5,"riseRate":0.4,"avgChangeRate":-0.039095},{"month":6,"riseRate":0.6,"avgChangeRate":0.061446},{"month":7,"riseRate":0.4,"avgChangeRate":-0.000641},{"month":8,"riseRate":0.6,"avgChangeRate":0.306524},{"month":9,"riseRate":0.6,"avgChangeRate":0.082474},{"month":10,"riseRate":0.6,"avgChangeRate":0.010604},{"month":11,"riseRate":0.4,"avgChangeRate":0.415594},{"month":12,"riseRate":0.6,"avgChangeRate":0.20601}],"exchange":"NASDAQ","name":"Terns Pharmaceuticals, Inc.","nameEN":"Terns Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Terns Pharmaceuticals, Inc.(TERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Terns Pharmaceuticals, Inc.,TERN,Terns Pharmaceuticals, Inc.股票,Terns Pharmaceuticals, Inc.股票老虎,Terns Pharmaceuticals, Inc.股票老虎国际,Terns Pharmaceuticals, Inc.行情,Terns Pharmaceuticals, Inc.股票行情,Terns Pharmaceuticals, Inc.股价,Terns Pharmaceuticals, Inc.股市,Terns Pharmaceuticals, Inc.股票价格,Terns Pharmaceuticals, Inc.股票交易,Terns Pharmaceuticals, Inc.股票购买,Terns Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Terns Pharmaceuticals, Inc.(TERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction